Blog

Blog

Event

Event

Press Releases

Press Releases

News

News

TCT Connect 2020

TCT Connect 2020

by TCT Connect 2020
 
246 people viewed this event.
TCT Connect 2020

Keystone Heart is pleased to share the results from REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR) have been accepted for presentation in a late-breaking clinical science session at the upcoming Cardiovascular Research Foundation TCT Connect Meeting.

 

The REFLECT Phase II study is a prospective, randomized, multi-center study evaluating the safety and effectiveness of the TriGUARD 3™ Cerebral Embolic Protection Device during TAVR.

 

Introducing

 

Presentation Title :REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR)
Date and Time :October 15th, 2020 at 11:20 am Eastern Time
Lecturer :Jeffrey W. Moses, MD, Director, Interventional Cardiovascular Therapeutics and Professor of Medicine at New York-Presbyterian/Columbia University Medical Center; REFLECT Trial Study Chairman

 
Join the session by registering at www.TCTConnect.com

 

The TriGUARD 3™ CEP Device is the only CE Marked cerebral embolic protection device designed to cover and protect all three cerebral vessels during transcatheter heart procedures

TCT Connect 2020

by TCT Connect 2020
 
246 people viewed this event.

To register for this event please visit the following URL:

 

Date And Time

2020-10-15 @ 11:20 AM to
 

Location

 

Venue

TCT Connect 2020
 
 
 

Share With Friends

No Comments

Sorry, the comment form is closed at this time.

Skip to content